The Joint Committee on Vaccination and Immunisation (JCVI) has recommended that teenagers be offered a meningitis B (MenB) vaccine on the NHS, a reversal of its position from just four months earlier and a direct response to a series of outbreaks that claimed teenage lives in early 2026. The Guardian

The advisory body, chaired by Prof Wei Shen Lim, laid out a multi-part programme on 16 July 2026. For children who received a MenB jab as a baby — those born on or after 1 May 2015 — the JCVI recommended a booster dose around age 15. The first cohort under that recommendation will turn 15 in 2030. Children who missed the infant MenB jab would receive two doses, administered at least 28 days apart. The committee also called for a catch-up programme so that anyone who misses a vaccine does not lose out.

The recommendation requires government approval, and each UK nation would decide on funding and implementation independently.

This marks a notable shift. As of 18 March 2026, the JCVI had not recommended a routine MenB booster vaccination for adolescents and young adults, according to the UK Health Security Agency. UKHSA The intervening months brought developments that clearly altered that calculus. The most serious outbreak hit Kent earlier in 2026 and left two teenagers dead. Among them was Juliette Kenny, 18, whose family subsequently campaigned for teenagers to routinely get access to the MenB vaccine.

The Kent outbreak reverberated well beyond public health guidance. In March 2026, pharmacies across the UK reported shortages of the MenB vaccine as demand surged, and the UK government released 20,000 NHS vaccine doses to the private market to address the supply gap. Reuters That intervention underscored the tension between existing NHS procurement structures and the realities of public demand during an active outbreak.

The JCVI's routine adolescent recommendation is separate from a one-off programme announced earlier in 2026. That programme offers the MenB vaccine to Year 13 pupils and to under-25 students starting university or residential education, with first doses available from 20 July 2026. UKHSA The routine recommendation, by contrast, is designed as an ongoing immunisation schedule rather than a time-limited response.

Data underpinning the JCVI's decision suggests the MenB vaccine provides strong protection for at least five years after vaccination. That durability profile makes a teenage booster viable for children who received the infant dose, since waning immunity during adolescence — a period of elevated risk for meningococcal disease — can be addressed before university entry, when transmission risk rises in congregate residential settings.

The broader context here is one of iterative policy calibration under public pressure. The JCVI's March 2026 non-recommendation sat alongside an active outbreak and grieving families calling for broader access. By July, the committee had moved to a recommendation covering routine adolescent vaccination, a catch-up programme, and a booster schedule. Whether the four-nation health departments move quickly enough to implement funding and delivery before the next academic year's university intake remains an open question, and one that the one-off summer programme was designed to bridge in the interim.

The separation between the one-off programme and the routine recommendation also carries implementation risk. Families and providers will need clear communication about eligibility to avoid confusion between a time-limited offer starting 20 July and a future routine schedule that, for the booster component, will not begin in earnest until 2030. The catch-up programme's scope and timeline will be critical for teenagers currently in the gap — too old for the infant programme, too young for the university-targeted one-off, and facing a multi-year wait before routine adolescent delivery reaches their cohort.